Tags

Type your tag names separated by a space and hit enter

Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Eur J Neurosci. 2011 May; 33(10):1823-31.EJ

Abstract

Levodopa-induced dyskinesias (LIDs) are abnormal involuntary movements induced by the chronic use of levodopa (l-Dopa) limiting the quality of life of Parkinson's disease (PD) patients. We evaluated changes of the serotonin 5-HT(2A) receptors in control monkeys, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys and in l-Dopa-treated MPTP monkeys, without or with adjunct treatments to inhibit the expression of LID: CI-1041, a selective NR1A/2B subunit antagonist of glutamate N-methyl-d-aspartic acid (NMDA) receptor, or Cabergoline, a long-acting dopamine D(2) receptor agonist. All treatments were administered for 1 month and animals were killed 24 h after the last dose of l-Dopa. Striatal concentrations of serotonin were decreased in all MPTP monkeys investigated, as measured by high-performance liquid chromatography. [(3) H]Ketanserin-specific binding to 5-HT(2A) receptors was measured by autoradiography. l-Dopa treatment that induced dyskinesias increased 5-HT(2A) receptor-specific binding in the caudate nucleus and the anterior cingulate gyrus (AcgG) compared with control monkeys. Moreover, [(3) H]Ketanserin-specific binding was increased in the dorsomedial caudate nucleus in l-Dopa-treated MPTP monkeys compared with saline-treated MPTP monkeys. Nondyskinetic monkeys treated with CI-1041 or Cabergoline showed low 5-HT(2A) -specific binding in the posterior dorsomedial caudate nucleus and the anterior AcgG compared with dyskinetic monkeys. No significant difference in 5-HT(2A) receptor binding was observed in any brain regions examined in saline-treated MPTP monkeys compared with control monkeys. These results confirm the involvement of serotonergic pathways and the glutamate/serotonin interactions in LID. They also support targeting 5-HT(2A) receptors as a potential treatment for LID.

Authors+Show Affiliations

Faculty of Pharmacy, Laval University, Quebec City, Canada.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21501255

Citation

Riahi, Golnasim, et al. "Brain 5-HT(2A) Receptors in MPTP Monkeys and Levodopa-induced Dyskinesias." The European Journal of Neuroscience, vol. 33, no. 10, 2011, pp. 1823-31.
Riahi G, Morissette M, Parent M, et al. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. Eur J Neurosci. 2011;33(10):1823-31.
Riahi, G., Morissette, M., Parent, M., & Di Paolo, T. (2011). Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. The European Journal of Neuroscience, 33(10), 1823-31. https://doi.org/10.1111/j.1460-9568.2011.07675.x
Riahi G, et al. Brain 5-HT(2A) Receptors in MPTP Monkeys and Levodopa-induced Dyskinesias. Eur J Neurosci. 2011;33(10):1823-31. PubMed PMID: 21501255.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias. AU - Riahi,Golnasim, AU - Morissette,Marc, AU - Parent,Martin, AU - Di Paolo,Thérèse, Y1 - 2011/04/19/ PY - 2011/4/20/entrez PY - 2011/4/20/pubmed PY - 2011/9/29/medline SP - 1823 EP - 31 JF - The European journal of neuroscience JO - Eur J Neurosci VL - 33 IS - 10 N2 - Levodopa-induced dyskinesias (LIDs) are abnormal involuntary movements induced by the chronic use of levodopa (l-Dopa) limiting the quality of life of Parkinson's disease (PD) patients. We evaluated changes of the serotonin 5-HT(2A) receptors in control monkeys, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned monkeys and in l-Dopa-treated MPTP monkeys, without or with adjunct treatments to inhibit the expression of LID: CI-1041, a selective NR1A/2B subunit antagonist of glutamate N-methyl-d-aspartic acid (NMDA) receptor, or Cabergoline, a long-acting dopamine D(2) receptor agonist. All treatments were administered for 1 month and animals were killed 24 h after the last dose of l-Dopa. Striatal concentrations of serotonin were decreased in all MPTP monkeys investigated, as measured by high-performance liquid chromatography. [(3) H]Ketanserin-specific binding to 5-HT(2A) receptors was measured by autoradiography. l-Dopa treatment that induced dyskinesias increased 5-HT(2A) receptor-specific binding in the caudate nucleus and the anterior cingulate gyrus (AcgG) compared with control monkeys. Moreover, [(3) H]Ketanserin-specific binding was increased in the dorsomedial caudate nucleus in l-Dopa-treated MPTP monkeys compared with saline-treated MPTP monkeys. Nondyskinetic monkeys treated with CI-1041 or Cabergoline showed low 5-HT(2A) -specific binding in the posterior dorsomedial caudate nucleus and the anterior AcgG compared with dyskinetic monkeys. No significant difference in 5-HT(2A) receptor binding was observed in any brain regions examined in saline-treated MPTP monkeys compared with control monkeys. These results confirm the involvement of serotonergic pathways and the glutamate/serotonin interactions in LID. They also support targeting 5-HT(2A) receptors as a potential treatment for LID. SN - 1460-9568 UR - https://www.unboundmedicine.com/medline/citation/21501255/Brain_5_HT_2A__receptors_in_MPTP_monkeys_and_levodopa_induced_dyskinesias_ L2 - https://doi.org/10.1111/j.1460-9568.2011.07675.x DB - PRIME DP - Unbound Medicine ER -